[1]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126-131.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
　Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):126-131.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
点击复制

分化型甲状腺癌的治疗进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第2期
页码:
126-131
栏目:
综述
出版日期:
2017-03-25

文章信息/Info

Title:
Advances in the treatment of differentiated thyroid cancer
作者:
张渊琪;  赵德善
030001 太原, 山西医科大学第二医院核医学科
Author(s):
Zhang Yuanqi;  Zhao Deshan
Department of Nuclear Medicine, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
分化型甲状腺癌; 辐射增敏药; 再分化诱导剂; 靶向药物治疗
Keywords:
Differentiated thyroid cancer; Radiation-sensitizing agents; Re-differentiation inducers; Targeted drug treatment
DOI:
10.3760/cma.j.issn.1673-4114.2017.02.009
摘要:
分化型甲状腺癌作为一种常见的低恶性肿瘤，通过“外科手术+131I治疗+甲状腺激素抑制治疗”三部曲的规范化治疗方案取得了良好的治疗效果。但部分治疗效果差的分化型甲状腺癌逐渐转化为低分化或失分化的难治性甲状腺癌，只能通过增敏和（或）再分化治疗来增加甲状腺癌细胞摄取131I的能力，以期提高131I治疗甲状腺癌的效果。对上述治疗手段无效的难治性甲状腺癌，靶向药物治疗技术的出现为其提供了广阔的治疗前景。笔者对使用增敏剂、再分化诱导剂和靶向药物治疗技术来提高分化型甲状腺癌治疗效果的研究进展进行了综述。
Abstract:
Differentiated thyroid cancers(DTC) are generally considered low-risk malignant tumors. Radioiodine ablation following thyroidectomy and thyroid hormone suppression therapy are standard treatment in patients with metastatic DTC. Patients with DTC obtain many benefits from a three-step therapy schedule(i.e., thyroidectomy+radioiodine ablation+thyroid hormone). A proportion of patients with locally advanced or metastatic disease and poorly differentiated or dedifferentiated thyroid cancer become refractory to radioactive 131I therapy. After sensitizer and/or redifferentiation inducer treatment, thyroid cancer cells in patients with refractory thyroid cancer increase 131I uptake and the effects of 131I treatment are improved for patients with refractory thyroid cancer. The emergence of targeted drug treatment technology provides a broad prospect for thyroid cancer refractory to 131I therapy. Progress in the areas of sensitizers, redifferentiation inducers, and targeted drug treatment techniques for treating thyroid cancer refractory to 131I therapy is discussed in this review.

参考文献/References:

[1] Wen Q, Ma Q, Bai L, et al. Glycididazole Sodium combined with radioiodine therapy for patients with differentiated thyroid carcinoma(DTC)[J]. Int J Clin Exp Med, 2015, 8(8):14095-14099.
[2] 陈滨. 甘氨双唑钠提高131I治疗分化型甲状腺癌颈淋巴结转移灶疗效的临床研究[D]. 吉林:吉林大学, 2010. Chen B. Clinical research of CMNa increased 131I treatment of differentiated thyroid cancer cervical lymph node metastases[D]. Jilin:Jilin University, 2010.
[3] 李晓敏, 晋建华, 武志芳, 等. 尼克酰胺对正常大鼠甲状腺辐射增敏作用的实验研究[J]. 医学研究杂志, 2012, 41(11):110-113. DOI:10. 3969/j. issn. 1673-548X. 2012. 11. 033. Li XM, Jin JH, Wu ZF, et al. An experimental study on radiation sensitizing effect of nicotinamide on normal thyroid in the rat[J]. J Med Res, 2012, 41(11):110-113.
[4] 苏慧东. siRNA-Bcl2增强人甲状腺癌FTC-133细胞131碘疗效的实验研究[D]. 郑州:郑州大学, 2013. Su HD. Study on siRNA-Bcl2 enhancing iodine-131 therapy effect in FTC-133 cell[D]. Zhengzhou:Zhengzhou University, 2013.
[5] 王瑞华. siRNA干扰Bcl2表达联合131碘治疗低分化甲状腺癌的实验研究[D]. 郑州:郑州大学, 2013. Wang RH. Studying the treatment of siRNA-BCL2 combined with 131Iodine for poorly differentiated thyroid carcinoma[D]. Zhengzhou:Zhengzhou University, 2013.
[6] 赖炜, 李俊杰. 131I照射对分化型甲状腺癌细胞摄碘水平及NISmRNA表达的影响[J]. 现代诊断与治疗, 2012, 23(11):1837-1838. DOI:10.3969/j.issn.1001-8174.2012.11.010 Lai W, Li JJ. Effect of 131I irradiation on radioiodine uptake in differentiated thyroid cancer cell and expression of NISmRNA. Mod Diagn Treat, 2012, 23(11):1837-1838.
[7] Kapiteijn E, Schneider TC, Morreau H, et al. New treatment modalities in advanced thyroid cancer[J]. Ann Oncol, 2012, 23(1):10-18. DOI:10. 1093/annonc/mdr117.
[8] Tepmongkol S, Keelawat S, Honsawek S, et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan:a correlation with the expression of peroxisome proliferator-activated receptor-gamma[J]. Thyroid, 2008, 18(7):697-704. DOI:10. 1089/thy. 2008. 0056.
[9] Fujii S, Srivastava V, Hegde A, et al. Regulation of AURKC expression by CpG island methylation in human cancer cells[J]. Tumour Biol, 2015, 36(10):8147-8158. DOI:10. 1007/s13277-015-3553-5.
[10] Wong KY, Chim CS. DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma[J]. Epigenomcis, 2015, 7(6):985-1001. DOI:10. 2217/epi. 15. 57.
[11] Ngamphaiboon N, Dy GK, Ma WW, et al. A phase I study of the histone deacetylase(HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors[J]. Invest New Drugs, 2015, 33(1):225-232. DOI:10. 1007/s10637-014-0174-6.
[12] Sharma K, Suresh PS, Mullangi R, et al. Quantitation of VEGFR2(vascular endothelial growth factor receptor)inhibitors-review of assay methodologies and perspectives[J]. Biomed Chromatogr, 2015, 29(6):803-834. DOI:10. 1002/bmc. 3370.
[13] Hanly EK, Rajoria S, Darzynkiewicz Z, et al. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype[J/OL]. BMC Res Notes, 2014, 7:187[2017-01-01]. https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-7-187. DOI:10. 1186/1756-0500-7-187.
[14] Xing J, Liu R, Xing M, et al. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032(RG7204)[J]. Biochem Biophys Res Commun, 2011, 404(4):958-962. DOI:10. 1016/j. bbrc. 2010. 12. 088.
[15] 周瑞瑜, 罗以. BRAFV600E和RAS基因突变与甲状腺癌远处转移及预后关系的研究进展[J]. 肿瘤药学, 2016, 6(3):178-181. DOI:10. 3969/j. issn. 2095-1264. 2016. 03. 04. Zhou RY, Luo Y. Research progress on the relationships of BRAFV600E and RAS gene mutation with distant metastasis and prognosis of thyroid carcinoma[J]. Anti-tumor Pharmacy, 2016, 6(3):178-181.
[16] Baratta MG, Porreca I, Di Lauro R. Oncogenic ras blocks the cAMP pathway and dedifferentiates thyroid cells via an impairment of pax8 transcriptional activity[J]. Mol Endocrinol, 2009, 23(6):838-848. DOI:10. 1210/me. 2008-0353.
[17] Huang W, Dong Z, Chen Y, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo[J]. Oncogene, 2016, 35(6):802. DOI:10. 1038/onc. 2015. 419.
[18] Dong W, Cui J, Tian X, et al. Aberrant sonic hedgehog signaling pathway and STAT3 activation in papillary thyroid cancer[J]. Int J Clin Exp Med, 2014, 7(7):1786-1793.
[19] Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma[J]. Science, 2013, 339(6122):959-961. DOI:10. 1126/science. 1230062.
[20] Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma[J]. Science, 2013, 339(6122):957-959. DOI:10. 1126/science. 1229259.
[21] Alzahrani AS, Alsaadi R, Murugan AK. TERT promoter mutations in thyroid cancer[J]. Horm Cancer, 2016, 7(3):165-177. DOI:10. 1007/s12672-016-0256-3.
[22] Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas[J]. J Clin Endocrinol Metab, 2014, 99(5):E754-765. DOI:10. 1210/jc. 2013-3734.
[23] Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940):319-328. DOI:10.1016/S0140-6736(14)60421-9.
[24] Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib(E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer:A clinical outcomes and biomarker assessment[J]. Cancer, 2015, 121(16):2749-2756. DOI:10. 1002/cncr. 29395.
[25] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7):621-630. DOI:10. 1056/NEJMoa1406470.
[26] Marotta V, Di Somma C, Rubino M, et al. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib[J]. Endocrine, 2015, 49(3):854-858. DOI:10. 1007/s12020-014-0448-y.
[27] Worden F, Fassnacht M, Shi Y, et al. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer[J]. Endocr Relat Cancer, 2015, 22(6):877-887. DOI:10. 1530/ERC-15-0252.
[28] Nair A, Lemery SJ, Yang J, et al. FDA approval summary:lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer[J]. Clin Cancer Res, 2015, 21(23):5205-5208. DOI:10. 1158/1078-0432. CCR-15-1377.
[29] Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib:Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments[J]. Cancer, 2014, 120(17):2694-2703. DOI:10. 1002/cncr. 28766.
[30] Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine:a nonrandomized, multicenter, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(9):1272-1282. DOI:http://dx. doi. org/10. 1016/S1470-2045(16)30166-8.
[31] Rothenberg SM, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAFV600E-mutant metastatic papillary thyroid cancer with dabrafenib-response[J]. Clin Cancer Res, 2015, 21(24):5640-5641. DOI:10. 1158/1078-0432. CCR-15-2298.
[32] Huillard O, Tenenbaum F, Clerc J, et al. Redifferentiation of iodine-refractory BRAFV600E-mutant metastatic papillary thyroid cancer with dabrafenib-letter[J]. Clin Cancer Res, 2015, 21(24):5639. DOI:10. 1158/1078-0432. CCR-15-1648.
[33] Chae IG, Kim DH, Kundu J, et al. Generation of ROS by CAY10598 leads to inactivation of STAT3 signaling and induction of apoptosis in human colon cancer HCT116 cells[J]. Free Radic Res, 2014, 48(11):1311-1321. DOI:10. 3109/10715762. 2014. 951838.

相似文献/References:

[1]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[2]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[3]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[4]刘晓秋,周则卫,沈秀,等.放射增敏剂尼可胺对Wistar大鼠致畸作用的研究[J].国际放射医学核医学杂志,2013,37(2):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
　LIU Xiao-qiu,ZHOU Ze-wei,SHEN Xiu,et al.Study on teratogenicity of Nikean in Wistar rats[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
[5]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[6]李卫红,王浩,周晓靓,等.肿瘤放射治疗增敏剂研究新进展[J].国际放射医学核医学杂志,2013,37(4):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
　LI Wei-hong,WANG Hao,ZHOU Xiao-liang,et al.Radiosensitizers development and the pathways[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
[7]刘晓秋,沈秀,王芹,等.尼可胺在大鼠体内的药代动力学研究[J].国际放射医学核医学杂志,2013,37(5):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
　LIU Xiao-qiu,SHEN Xiu,WANG Qin,et al.Study on pharmacokinetics of NiKeAn in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
[8]叶智轶,王辉,吴靖川.维甲酸在诱导再分化治疗分化型甲状腺癌中的价值[J].国际放射医学核医学杂志,2007,31(4):221.
　YE Zhi-yi,WANG Hui,WU Jing-chuan.The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):221.
[9]李玉,董丹,阎英.肿瘤辐射增敏机制研究进展[J].国际放射医学核医学杂志,2007,31(1):48.
　LI Yu,DONG Dan,Yah Ying.The development of radiosensitizer mechanisms[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):48.
[10]顾菲,刘晓秋.肿瘤辐射增敏的分子机制[J].国际放射医学核医学杂志,2006,30(5):298.
　GU Fei,LIU Xiao-qiu.The molecular mechanism of tumor radiosensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):298.

备注/Memo

备注/Memo:
收稿日期:2017-01-06。
通讯作者:赵德善,Email:deshanzh@163.com
更新日期/Last Update: 2017-04-24